Wenwang Lang - Publications

Economic value of finotonlimab plus bevacizumab versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma in China and the United States.

Journal: Frontiers in public health

Published: January 10, 2026

Cost-effectiveness of cadonilimab plus chemotherapy vs chemotherapy alone for advanced gastric cancer: evidence to inform drug pricing in the U.S. and China.

Journal: Frontiers in immunology

Published: April 26, 2025

Cost-effectiveness analysis of toripalimab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China.

Journal: Frontiers in pharmacology

Published: April 23, 2025

Cost-effectiveness of socazolimab plus chemotherapy vs. standard chemotherapy for first-line treatment of extensive-stage small cell lung cancer: a U.S. and China perspective.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 02, 2025

Exploring resistance to initial chemotherapy in small cell lung cancer: The role of bone metastasis and other clinicopathologic characteristics.

Journal: Medicine

Published: March 24, 2025

Cost-effectiveness of cabozantinib versus placebo for advanced neuroendocrine tumors from crossover-adjusted analysis in the United States and China.

Journal: Scientific reports

Published: February 14, 2025

Cost-effectiveness analysis of benmelstobart and anlotinib plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: Perspectives from the United States and China.

Journal: PloS one

Published: September 10, 2024

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: July 09, 2024

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China.

Journal: Frontiers in pharmacology

Published: July 08, 2024

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China.

Journal: International journal of clinical pharmacy

Published: May 20, 2024

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in the Chinese healthcare system.

Journal: Frontiers in pharmacology

Published: March 19, 2024

Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System.

Journal: Clinical drug investigation

Published: January 16, 2024